NeuroDerm's ND0612 Study Evaluates Safety and Pharmacokinetics in Parkinson's Disease
A randomized, placebo-controlled study is underway to assess the safety and pharmacokinetics of ND0612 in Parkinson's disease patients.
Phase III
Parkinson's Disease market
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing study of ND0612 is critical as it may significantly enhance treatment options for Parkinson's disease patients, particularly those experiencing motor fluctuations. Positive outcomes could solidify NeuroDerm's competitive position in the neurology market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for results on safety, tolerability, and pharmacokinetics, as well as any announcements regarding pump usability and clinical effects.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.